Release
📈 Stocks
MaxCyte to Acquire Akron Bio for $151.8 Million to Double Revenue Base
(just now)
MaxCyte will acquire Akron Bio for $151.8 million, utilizing a mix of cash, stock, and a new $75.0 million credit facility to…